Zurück zu Schlaf
Schlaf

CBD for SleepStudienlage & Dosis

Endocannabinoid-System, REM-Effekte und Dosierungs-Spektrum.

Studien zuletzt aktualisiert

Studienlage in Zahlen

Studien gesamt
1.000
Mit Abstract
50
Meta / Systematic / RCT
144
Häufig zitiert
50
Erscheinungsjahre
1975–2026

CBD for Sleep im Kontext von Schlaf

Dieses Thema ist Teil unserer Welt „Schlaf". Dort findest du Methodik, Studienlage und Hebel mit dem größten Effekt — sowie die Reihenfolge, in der sich Hebel sinnvoll aufeinander aufbauen.

Zur Welt Schlaf

Top-Studien zu CBD for Sleep

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

  1. Cannabis-based medicines for chronic neuropathic pain in adults.

    Cochrane Database Syst Rev2018n=175Meta-Analysis200 einflussreiche Zitationen

    <h4>Background</h4>This review is one of a series on drugs used to treat chronic neuropathic pain. Estimates of the population prevalence of chronic pain with neuropathic components range between 6% and 10%. Current pharmacological…

    Befund: Cannabis-based medicines may increase the number of adults with chronic neuropathic pain who achieve 50% or greater pain relief compared with placebo.

  2. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.

    Lancet Psychiatry2019n=306Meta-Analysis200 einflussreiche Zitationen

    <h4>Background</h4>Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic…

  3. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.

    BMJ2023n=101Systematic Review200 einflussreiche Zitationen

    Objective To systematically assess credibility and certainty of associations between cannabis, cannabinoids, and cannabis based medicines and human health, from observational studies and randomised controlled trials (RCTs). Design Umbrella…

  4. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

    Neurology2005n=66RCT148 einflussreiche Zitationen

    <h4>Background</h4>Central pain in multiple sclerosis (MS) is common and often refractory to treatment.<h4>Methods</h4>We conducted a single-center, 5-week (1-week run-in, 4-week treatment), randomized, double-blind, placebo-controlled,…

  5. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials.

    Neuropsychopharmacology2020n=803Meta-Analysis148 einflussreiche Zitationen

    Cannabidiol (CBD) is being investigated as a treatment for several medical disorders but there is uncertainty about its safety. We conducted the first systematic review and meta-analysis of the adverse effects of CBD across all medical…

  6. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.

    J Pain Symptom Manage2010n=177RCT147 einflussreiche Zitationen

    This study compared the efficacy of a tetrahydrocannabinol:cannabidiol (THC:CBD) extract, a nonopioid analgesic endocannabinoid system modulator, and a THC extract, with placebo, in relieving pain in patients with advanced cancer. In…

  7. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

    Mult Scler2004n=160RCT123 einflussreiche Zitationen

    The objective was to determine whether a cannabis-based medicinal extract (CBME) benefits a range of symptoms due to multiple sclerosis (MS). A parallel group, double-blind, randomized, placebo-controlled study was undertaken in three…

  8. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.

    BMC Psychiatry2020n=13Systematic Review121 einflussreiche Zitationen

    Background Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity,…

  9. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.

    BMC Med2022n=12.123Meta-Analysis120 einflussreiche Zitationen

    Background Medical cannabinoids differ in their pharmacology and may have different treatment effects. We aimed to conduct a pharmacology-based systematic review (SR) and meta-analyses of medical cannabinoids for efficacy, retention and…

  10. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.

    Trends Psychiatry Psychother2024n=60RCT114 einflussreiche Zitationen

    <h4>Objective</h4>Autism spectrum disorder (ASD) is characterized by persistent deficits in social communication and social interaction and by restricted and repetitive patterns of behavior. Some studies have shown that substances derived…

Häufige Fragen

Was sagt die Studienlage zu CBD for Sleep?
Cannabis-based medicines may increase the number of adults with chronic neuropathic pain who achieve 50% or greater pain relief compared with placebo.
Welche Dosierung wurde in den Studien untersucht?
• Cannabis-based medicines (herbal cannabis, plant-derived THC/CBD oromucosal spray, synthetic THC mimic nabilone, plant-derived THC dronabinol) (Not reported) • Medicinal cannabinoids, including medicinal cannabis, pharmaceutical cannabinoids, THC, CBD, and synthetic derivatives (Not reported) • Cannabis, cannabinoids, and cannabis based medicines (Not reported)
Gibt es Sicherheitshinweise zu CBD for Sleep?
• Withdrawals due to adverse events were higher with cannabis-based medicines than placebo. • Nervous system adverse events were more common with cannabis-based medicines. • Psychiatric disorders were more common with cannabis-based medicines. • Long-term risks were not reported.

Weitere Themen in Schlaf

Glycin

Glycin, Schlafqualität, Körpertemperatur und Sicherheit.

Alkohol & Schlaf

Schnelleres Einschlafen, aber REM-Suppression und Wach-Phasen.

Antihistaminika

Diphenhydramin, Doxylamin — Schlaf-Frags, anticholinerge Demenz-Risiken.

Apigenin

Kamille, GABA-Modulation und Schlafqualität.

Apigenin (Schlaf)

Flavonoid aus Kamille, GABA-Modulation, Schlafqualität.

Ashwagandha (Schlaf)

Cortisol-Senkung, Schlafqualität — KSM-66 und Sensoril-Extrakte.

Dunkelheit

Blackout-Vorhänge, Schlafmaske — Melatonin und Schlaftiefe.

Raumtemperatur

Optimal 17-19°C — Körperkerntemperatur-Abfall fördert Schlaf.

Benzodiazepine

Sedativum/Hypnotikum — Abhängigkeit, kognitive Risiken im Alter.

Blaulichtfilter

f.lux, Night Shift, Brillen — Evidenz und Marketing-Hype.

Bruxismus

Zähneknirschen — Stress, Schiene, Trigger-Faktoren.

Koffein-Timing

Halbwertszeit ~5-6h — Cut-off 8-10h vor Schlaf.

CBT-I

Kognitive Verhaltenstherapie für Insomnie — Erstlinien-Therapie laut Leitlinie.

Circadianer Rhythmus

Innere ~24h-Uhr — Licht als Hauptsignal, periphere Uhren in Organen.

CPAP

Continuous Positive Airway Pressure — Standard bei mittelschwerer Apnoe.

Tiefschlaf

N3-Slow-Wave-Sleep — körperliche Regeneration, GH-Ausschüttung.

GABA Supplements

Blut-Hirn-Schranke, fermentiertes GABA und Wirksamkeits-Daten.

Glycine for Sleep

Tiefschlaf, Körpertemperatur-Senkung und 3g abends.

Glycin (Schlaf)

3g vor dem Schlaf — Körperkerntemperatur-Senkung, Tiefschlaf-Modulation.

Glymphatisches System

Gehirn-Detox während Schlaf — Beta-Amyloid-Clearance.

Verwandte Themen aus anderen Welten